Mer­ck ex­pands scope of Zymeworks an­ti­body al­liance, adding close to $900M in mile­stones

Near­ly a decade af­ter first part­ner­ing with Mer­ck, Van­cou­ver-based biotech Zymeworks has ex­pand­ed its col­lab­o­ra­tion with the phar­ma gi­ant once again.

Zymeworks re-upped with Mer­ck in a new li­cens­ing agree­ment, grant­i­ng the New Jer­sey phar­ma gi­ant the right to de­vel­op up to 3 ad­di­tion­al mul­ti­spe­cif­ic an­ti­body can­di­dates. In ex­change, the biotech will re­ceive an undis­closed up­front pay­ment — Mer­ck is al­ways loath to dis­cuss cash terms — and near­ly $900 mil­lion in com­bined reg­u­la­to­ry ($411 mil­lion) and com­mer­cial ($480 mil­lion) mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.